Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE ER versus EXTENDED PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE ER versus EXTENDED PHENYTOIN SODIUM.
DEPAKOTE ER vs EXTENDED PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%)
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant